Here is the good news when it comes to issue of regulating cannabinoids. Last month, the European Commission added Cannabigerol (CBG) to the Cosing List—namely the regional database of allowable ingredients in cosmetics. This after adding natural CBD as an approved substance the month before.
The process of regulating cannabinoids in Europe is well underway. From one perspective, this makes sense. Each cannabinoid is a unique chemical compound. So are other components of the plant—such as terpenes. However, so far, there has never been a regulatory investigation of the entire plant, compound by compound by any national or regional authority. The EU approach to regulation is, in other words, highly unique in the history of the plant itself.
How does this procedure of regulating cannabinoids at the European level integrate with approval of cannabis for both medical and non-medical use? And for what purpose?
The Process of Regulating Cannabinoids For All Uses
Part of the difference now being seen in Europe with regards to regulatory approaches is that first and foremost, certainly after acceptance of its medical efficacy, cannabis as a plant genus is dealt with as a naturally occurring mixture of many